Bayer AG
XHAM:BAYN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bayer AG
Operating Income
Bayer AG
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Bayer AG
XETRA:BAYN
|
Operating Income
€6B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Operating Income
-$111.3m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Merck KGaA
XETRA:MRK
|
Operating Income
€4.3B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
MPH Health Care AG
XETRA:93M1
|
Operating Income
-€1.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Operating Income
€244.1m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Operating Income
€1.3m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bayer AG
Glance View
Bayer AG, a German multinational behemoth, traces its roots back to 1863 in Barmen, when Friedrich Bayer and Johann Friedrich Weskott began their enterprise as a dye-making factory. Fast forward to the present day, and Bayer has evolved into a global powerhouse, seamlessly weaving through pharmaceuticals, consumer health, and agricultural science. At its core, Bayer’s business operations spin around its three main segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division is the jewel in Bayer’s crown, focusing on prescription medicines across various therapeutic areas such as oncology, cardiology, and gynecology, allowing Bayer to cater to the world's increasing demand for healthcare solutions, which not only drive patient outcomes but also account for a significant chunk of revenue. Not to be overshadowed, Bayer’s Crop Science division plays a pivotal role, emphasizing its strong commitment to sustainable agriculture. Here, the company develops seeds, traits, and crop protection products that appeal to farmers seeking to enhance yield and manage crop threats. Meanwhile, the Consumer Health division targets over-the-counter products, covering a range of everyday health issues, resonating with consumers seeking self-care solutions. Bayer’s ability to seamlessly integrate its scientific prowess into real-world applications enables the company to extract value across these sectors, creating an intricate mosaic of interdependent streams of revenue and continually reinforcing its stature as a leader in life sciences.
See Also
What is Bayer AG's Operating Income?
Operating Income
6B
EUR
Based on the financial report for Dec 31, 2025, Bayer AG's Operating Income amounts to 6B EUR.
What is Bayer AG's Operating Income growth rate?
Operating Income CAGR 10Y
-1%
Over the last year, the Operating Income growth was 83%. The average annual Operating Income growth rates for Bayer AG have been -9% over the past three years , and -1% over the past ten years .